ASPP2 reduction attenuates HBV induced chronic liver damage: A hybrid mouse model study

Area of Science:

• Hepatology
• Molecular Biology
• Immunology

Background:

• P53 Apoptosis Stimulating Protein 2 (ASPP2) plays a role in cellular processes like apoptosis and proliferation.
• The specific function of ASPP2 in Hepatitis B virus (HBV) infection and its impact on chronic liver damage remain largely uncharacterized.

Purpose of the Study:

• To investigate the role of ASPP2 in the context of HBV infection.
• To explore the effect of ASPP2 modulation on HBV-induced chronic liver damage.

Main Methods:

• Transcriptome profiling using RNA-sequencing on liver tissues from ASPP2-knockdown and HBV-ASPP2-knockdown mice.
• Analysis of liver pathology via Hematoxylin and Eosin (HE) staining, and immunohistochemistry (F4/80, MPO).
• Biochemical assessment of liver injury markers (ALT, AST) and gene expression analysis (PCR, Western Blot).

Main Results:

• ASPP2 knockdown alone showed minimal liver pathology but altered immune and metabolic pathways.
• In HBV-infected mice, ASPP2 knockdown reduced liver inflammation, cell damage, and serum ALT/AST levels.
• ASPP2 knockdown significantly altered immune and inflammatory responses in HBV-infected livers, with PPAR pathway modulation identified as a key mechanism, specifically an increase in PPARγ.

Conclusions:

• Reduction of ASPP2 mitigates HBV-induced hepatocyte damage during chronic infection.
• The protective effect is linked to ASPP2's differential regulation of PPARγ in the presence and absence of HBV stimulation.